CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 109 enrolled
Drug / intervention
Diamyd +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03345004
NCT03345004Phase 2Completed

A Phase IIb, 2-Arm, Randomized, Double-blind, Placebo-Controlled, Multicentre Study to Optimize Diamyd Therapy Administered Into Lymph Nodes Combined With Oral Vitamin D to Investigate the Impact on the Progression of Type 1 Diabetes

Diamyd Medical AB·interventional·Posted Nov 17, 2017·Updated Jan 9, 2023

In Brief

A Phase 2 clinical trial evaluating Diamyd, Vitamin D, and 2 other interventions for Diabetes Mellitus, Type 1 and 11 related conditions. Completed, enrolled 109 participants across 18 sites in 4 countries.

Detailed Summary

The objective of DIAGNODE-2 is to evaluate the efficacy of Diamyd compared to Placebo, upon administration directly into a lymph node in combination with an oral vitamin D/Placebo regimen, in terms of preserving endogenous insulin secretion as measured by C-peptide.

Study Details

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedNov 17, 2017
Enrollment StartDec 20, 2017
Primary CompletionJul 13, 2020
Study CompletionApr 27, 2021
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 8.6 years ago

Interventions

Diamydbiological

Alhydrogel®-formulated recombinant human glutamic acid decarboxylase (rhGAD65)

Vitamin Ddietary

Oil suspension of Vitamin D

Placebo for Diamydbiological

Alhydrogel® only

Placebo for Vitamin Ddietary

Placebo oil suspension for Vitamin D